Literature DB >> 33792967

Telephone consultation for myasthenia gravis care during the COVID-19 pandemic: Assessment of a novel virtual myasthenia gravis index.

Deepak Menon1, Sara Alnajjar1, Carolina Barnett1, Joy Vijayan1, Hans Katzberg1, Davood Fathi1, Monica Alcantara1, Vera Bril1.   

Abstract

INTRODUCTION/AIMS: The aim of the study was to determine the association between the virtual Myasthenia Gravis Impairment Index (vMGII) with other patient-reported outcomes (PROs) of myasthenia gravis (MG) and its usefulness in telephone consultations with MG patients.
METHODS: This was a retrospective case series in which vMGII score along with virtual Single Simple Question (vSSQ), virtual Patient-Acceptable Symptom State PASS (vPASS) response, and patient disease status based on Myathenia Gravis Foundation of America postintervention status were collected during telephone consultation along with the MGII, SSQ, and PASS responses during the preceding in-person clinic visits.
RESULTS: In 214 patients, the mean difference of vMGII between the vPASS "Yes" and "No" groups was -14.2 ± 1.4 (95% confidence interval, -16.9 to -11.3; P < .001) with mean vMGII for vPASS "Yes" group being 6.4 ± 7.7 and vPASS "No" being 20.5 ± 11.5. A vMGII of 11.5 or higher predicted vPASS "yes" response with a sensitivity of 78.7% and specificity of 81.4%. A strong negative correlation was found between the vMGII and vSSQ (r = -.667; P < .001). The mean vMGII was 0.48 ± 1.42 for patients in remission, and 9.31 ± 10.93 for improved, 9.32 ± 8.79 for stable, and 22.58 ± 14.04 for worsened groups (P < .001). These associations were the same as those obtained during the preceding in-person clinic visit and the direction of change in MGII scores also indicated change in disease status. DISCUSSION: vMGII is an effective measure to assess an MG patient's disease status in telephone consultations and relates well with other PRO measures. The vMGII remains reliable for assessing MG disease status even with removal of the physical examination component.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  Myasthenia Gravis Impairment Index; myasthenia gravis; patient-reported outcomes; telephone consultation

Mesh:

Year:  2021        PMID: 33792967     DOI: 10.1002/mus.27243

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.

Authors:  Antonino Lupica; Vincenzo Di Stefano; Salvatore Iacono; Antonia Pignolo; Martina Quartana; Andrea Gagliardo; Brigida Fierro; Filippo Brighina
Journal:  Neurol Int       Date:  2022-04-27

2.  Development and validation of the Myasthenia Gravis TeleScore (MGTS).

Authors:  F Pasqualin; S V Guidoni; E Albertini; M Ermani; R Frangiamore; F Vanoli; C Antozzi; R Mantegazza; D M Bonifati
Journal:  Neurol Sci       Date:  2022-02-28       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.